Development of Highly Potent Noncovalent Inhibitors of SARS-CoV-2 3CLpro

Ningke Hou; Lei Shuai; Lijing Zhang; Xuping Xie; Kaiming Tang; Yunkai Zhu; Yu Yin; Wenyi Zhang; Qiaozhu Tan; Gongxun Zhong; Zhiyuan Wen; Chong Wang; Xijun He; Hong Huo; Haishan Gao; You Xu; Jing Xue; Chen Peng; Jing Zou; Craig Schindewolf; Vineet D. Menachery; Wenji Su; Youlang Yuan; Zuyuan Shen; Rong Zhang; Shuofeng Yuan; Hongtao Yu; Pei‐Yong Shi; Zhigao Bu; Jing Huang; Qi Hu

doi:10.1021/acscentsci.2c01359

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

values in the 10-nM range. WU-04 also inhibits the 3CLpro of SARS-CoV and MERS-CoV with high potency, indicating that it is a pan-inhibitor of coronavirus 3CLpro. WU-04 showed anti-SARS-CoV-2 activity similar to that of PF-07321332 (Nirmatrelvir) in K18-hACE2 mice when the same dose was administered orally. Thus, WU-04 is a promising drug candidate for coronavirus treatment.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Hou et al. (2023) studied this question.

synapsesocial.com/papers/6a037935ff0a4a103d01d6b1 https://doi.org/10.1021/acscentsci.2c01359

View Full Paper

Ask AI

Bookmark

Share

Development of Highly Potent Noncovalent Inhibitors of SARS-CoV-2 3CLpro

Ask about this paper

Abstract

Discussion

Cite This Study

Development of Highly Potent Noncovalent Inhibitors of SARS-CoV-2 3CLpro

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading